U.S. Markets open in 6 hrs 28 mins

Sight Sciences, Inc. (SGHT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.01-1.57 (-6.14%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close25.58
Open25.00
Bid0.00 x 1400
Ask0.00 x 1300
Day's Range23.72 - 25.68
52 Week Range23.72 - 42.57
Volume518,175
Avg. Volume441,491
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.67
  • GlobeNewswire

    Sight Sciences Files Lawsuit Against Ivantis for Patent Infringement

    Sight Sciences Seeks Injunction Related to Hydrus® Microstent’s InfringementMENLO PARK, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ: SGHT) today announced that it filed a lawsuit in the United States District Court in Delaware against Ivantis, Inc. for infringement of U.S. Patent Numbers 8,287,482, 9,370,443, 9,486,361, and 10,314,742. These patents describe and claim devices and methods for reducing intraocular pressure in the eye. Sight Sciences’ complaint seeks an

  • GlobeNewswire

    Sight Sciences to Participate in the Morgan Stanley Global Healthcare Conference

    MENLO PARK, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world's most prevalent eye diseases, today announced plans to participate in the upcoming virtual Morgan Stanley Global Healthcare Conference. Sight Sciences’ management is scheduled to present Thursday, September 9, 2021 at 9:30am ET. Interested parties may access a live

  • GlobeNewswire

    Sight Sciences, Pioneering the Development of the Standalone MIGS Market, Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma

    Real-world data published in Clinical Ophthalmology show the safety, efficacy, and durability of effect of OMNI for use in a standalone procedure to reduce intraocular pressure and medication burdenMENLO PARK, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world's most prevalent eye diseases, today announced publication in Clinic